Enrollment is underway in a Phase 2 clinical trial evaluating Aravive’s (ARAV -2.6%) lead candidate AVB-500 in patients with IgA nephropathy, also known as Berger’s disease, characterized by the gradual buildup of immunoglobulin A (IgA) in the kidneys which leads to inflammation and comprised organ function.
Primary endpoints of the 24-subject study include safety and a range of efficacy measures. The estimated primary completion date is December 2020.
The company says AVB-500 is an ultra-high affinity decoy protein that suppresses fibrosis (scarring) and cancer cell proliferation by capturing and binding to a protein called GAS6, overexpressed in Berger’s disease and ovarian cancer.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.